https://www.oncolines.com/blog/2021/04/05/webinar-how-to-overcome-acquired-resistance-against-kinase-inhibitors/2024-07-04T15:18:55+02:00https://www.oncolines.com/blog/2021/04/28/phosphorylation-status-determines-kinase-inhibitor-binding/2024-07-04T15:19:35+02:00https://www.oncolines.com/blog/2021/05/25/case-study-altered-drug-response-in-3d-spheroids/2024-07-04T15:20:07+02:00https://www.oncolines.com/blog/2021/06/18/webinar-comparative-cancer-cell-panel-profiling-of-recently-approved-kinase-inhibitors/2024-07-04T15:30:27+02:00https://www.oncolines.com/blog/2021/09/28/ntrc-precision-medicine-services-is-now-oncolines/2021-09-28T08:19:21+02:00https://www.oncolines.com/blog/2021/11/02/oncolines-opens-a-new-screening-lab/2023-01-29T01:06:18+01:00https://www.oncolines.com/blog/2021/11/19/case-study-combination-matrix-to-determine-bliss-independence-synergy-scores/2024-07-04T15:11:00+02:00https://www.oncolines.com/blog/2022/02/04/news-flash-oncolinesprofiler-library-is-approaching-the-200-mark/2024-07-04T15:11:30+02:00https://www.oncolines.com/blog/2022/03/03/oncolines-news-flash/2024-07-04T15:12:15+02:00https://www.oncolines.com/blog/2022/03/09/oncolines-news-flash-2/2022-03-15T12:03:17+01:00https://www.oncolines.com/blog/2022/03/31/oncolines-contributes-to-a-proposed-new-combination-treatment-strategy-for-pediatric-acute-lymphoblastic-leukemia-published-in-nature-communication/2024-07-04T15:12:37+02:00https://www.oncolines.com/blog/2022/04/14/case-study-gene-expression-profiling-to-understand-and-combat-drug-resistance/2024-07-04T15:12:59+02:00https://www.oncolines.com/blog/2022/05/11/oncolines-hosts-upcoming-webinar-how-to-select-the-best-platform-for-testing-drug-combinations/2022-07-29T14:49:52+02:00https://www.oncolines.com/blog/2022/07/29/on-demand-webinar-on-cancer-genomics/2023-04-03T17:27:57+02:00https://www.oncolines.com/blog/2022/09/15/new-in-frontiers-in-oncology-comparative-profiling-study-of-newly-approved-kinase-inhibitors/2024-07-04T15:13:25+02:00https://www.oncolines.com/blog/2023/01/10/oncolines-team-joins-symeres/2024-07-04T15:13:43+02:00https://www.oncolines.com/blog/2023/02/08/new-oncolines-publication-in-cancers/2023-02-08T13:39:24+01:00https://www.oncolines.com/blog/2023/03/30/our-upcoming-webinar-biomarkers-for-patient-stratification-and-target-engagement/2023-04-05T17:08:56+02:00https://www.oncolines.com/blog/2023/07/27/new-oncolines-publication-in-cancer-chemotherapy-and-pharmacology-cancers/2024-07-04T15:14:03+02:00https://www.oncolines.com/blog/2023/09/01/target-identification-of-hits-from-a-phenotypic-screen/2024-07-04T15:14:43+02:00https://www.oncolines.com/blog/2023/09/20/100-years-pharmaceutical-industry-in-oss/2026-04-06T12:39:42+02:00https://www.oncolines.com/blog/2023/10/04/oncolines-at-aacr-nci-eortc-2023-in-boston/2024-07-04T15:15:06+02:00https://www.oncolines.com/blog/2023/10/18/oncolines-presentation-at-revvity-symposium-ghent/2023-10-18T21:00:09+02:00https://www.oncolines.com/blog/2024/01/11/new-bioinformatics-service-proteomicsprofiler/2024-01-17T16:50:26+01:00https://www.oncolines.com/blog/2024/01/17/oncolines-contributes-to-publication-in-nature-communications/2024-03-11T17:01:14+01:00https://www.oncolines.com/blog/2024/03/11/oncolines-contributes-to-publication-in-mucosal-immunology-biacore-studies-prove-binding-of-bacterial-lysate-om-85-to-toll-like-receptors/2024-10-22T08:41:06+02:00https://www.oncolines.com/blog/2024/04/02/compound-profiling-in-parp-inhibitor-resistant-cancer-cell-lines/2024-04-02T11:05:31+02:00https://www.oncolines.com/blog/2024/04/04/compound-profiling-on-egfr-mutants-and-osimertinib-resistant-cell-lines/2024-06-17T09:39:31+02:00https://www.oncolines.com/blog/2024/04/03/cancer-cell-panel-profiling-of-mapk-pathway-inhibitors/2024-06-17T09:39:02+02:00https://www.oncolines.com/blog/2024/06/18/expansion-of-residencetimer-kinase-panel/2024-10-23T08:55:34+02:00https://www.oncolines.com/blog/2024/08/08/new-publication-in-frontiers-in-immunology/2024-08-15T11:56:06+02:00https://www.oncolines.com/blog/2024/09/05/cell-toxicity-as-alternative-readout/2024-10-21T17:15:13+02:00https://www.oncolines.com/blog/2024/10/22/oncolines-launches-ido2-assay/2024-10-22T16:37:46+02:00https://www.oncolines.com/blog/2024/10/22/new-oncolines-case-study/2024-10-22T16:37:29+02:00https://www.oncolines.com/blog/2024/10/24/compound-profiling-in-drug-resistant-cell-lines/2024-10-22T16:38:05+02:00https://www.oncolines.com/blog/2024/12/12/new-case-study-featuring-genenominator-gene-expression-analysis/2024-12-12T14:17:11+01:00https://www.oncolines.com/blog/2024/12/19/expansion-of-anti-cancer-therapeutics-reference-library/2024-12-19T14:42:03+01:00https://www.oncolines.com/blog/2026/05/21/anti-cancer-agent-reference-library-covers-new-targets-and-mechanisms-of-action/2026-05-22T16:30:20+02:00https://www.oncolines.com/blog/2026/04/14/understanding-drug-activity-and-resistance-through-broad-cancer-cell-line-profiling/2026-05-22T16:47:41+02:00https://www.oncolines.com/blog/2026/01/15/collection-of-patient-derived-cancer-cell-models-with-clinically-relevant-alterations/2026-05-29T15:52:55+02:00https://www.oncolines.com/blog/2025/10/27/potential-application-of-btk-inhibitor-nemtabrutinib-in-mapk-driven-cancers/2026-05-29T16:20:18+02:00https://www.oncolines.com/blog/2026/05/05/accelerating-molecular-glue-discovery/2026-05-29T16:53:22+02:00https://www.oncolines.com/blog/2026/06/02/exploring-binding-kinetics-of-antibody-drug-conjugates/2026-06-02T13:05:06+02:00